Brought to you by 
Isis and Alnylam in RNAi deal
20 May 2005
Executive Summary
In a product swap agreement involving double-stranded RNAi patents, Isis Pharmaceuticals licensed Alnylam Pharmaceuticals (therapeutics based on RNAi) rights to its patent estate relating to antisense mechanisms and oligonucleotide chemistry. In turn, Alnylam provided Isis with rights to its patent applications. The companies plan to develop and commercialize RNAi therapeutics.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Intra-Biotech Deal
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Isis and Alnylam in RNAi deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice